(Q36646204)

15 August 2017

Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen (English)

1 reference

15 August 2017

1 reference

1 reference

S Slater

1

1 reference

15 August 2017

J Shamash

2

1 reference

15 August 2017

P Wilson

3

1 reference

15 August 2017

C J Gallagher

4

1 reference

15 August 2017

M L Slevin

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

87

1 reference

15 August 2017

8

1 reference

15 August 2017

850-853

1 reference

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

Gastric cancer: overview of current therapies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376181

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

28 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12373598

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12373598

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600553

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6600553

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

12373598

1 reference